Integrated sensor-augmented pump therapy system [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation

Review suggests Veo system appears to be better than other systems considered at reducing hypoglycaemic events, but in adults, it is unlikely to be cost-effective. Integrated systems are also generally unlikely to be cost-effective vs. stand-alone systems.

Recently, NICE diagnostic guidance supported the use of the MiniMed Paradigm Veo system as an option for managing blood glucose levels in people with type 1 diabetes only if:

 

• they have episodes of disabling hypoglycaemia despite optimal management with continuous subcutaneous insulin infusion and

• the company arranges to collect, analyse and publish data on the use of the MiniMed Paradigm Veo system.

 

The guidance recommends that the MiniMed Paradigm Veo system should be used under the supervision of a trained multidisciplinary team who are experienced in continuous subcutaneous insulin infusion and continuous glucose monitoring for managing type 1 diabetes only if the person or their carer:

 

• agrees to use the sensors for at least 70% of the time

• understands how to use it and is physically able to use the system and

• agrees to use the system while having a structured education programme on diet and lifestyle, and counselling.

 

The guidance did not support the routine adoption in the NHS of the Vibe and G4 PLATINUM CGM system for managing blood glucose levels in people with type 1 diabetes as there was currently insufficient evidence, though it was considered promising.